JP5586598B2 - 安定化剤、および1種類以上の弱毒生フラビウイルスを含むワクチン組成物 - Google Patents
安定化剤、および1種類以上の弱毒生フラビウイルスを含むワクチン組成物 Download PDFInfo
- Publication number
- JP5586598B2 JP5586598B2 JP2011517028A JP2011517028A JP5586598B2 JP 5586598 B2 JP5586598 B2 JP 5586598B2 JP 2011517028 A JP2011517028 A JP 2011517028A JP 2011517028 A JP2011517028 A JP 2011517028A JP 5586598 B2 JP5586598 B2 JP 5586598B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- vaccine composition
- live attenuated
- vaccine
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 109
- 229960005486 vaccine Drugs 0.000 title claims description 67
- 230000002238 attenuated effect Effects 0.000 title claims description 37
- 241000710831 Flavivirus Species 0.000 title claims description 36
- 239000003381 stabilizer Substances 0.000 title claims description 34
- 241000700605 Viruses Species 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 41
- 208000003152 Yellow Fever Diseases 0.000 claims description 38
- 239000011324 bead Substances 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 30
- 208000001490 Dengue Diseases 0.000 claims description 24
- 206010012310 Dengue fever Diseases 0.000 claims description 24
- 208000025729 dengue disease Diseases 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 24
- 238000004108 freeze drying Methods 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000006641 stabilisation Effects 0.000 claims description 10
- 238000011105 stabilization Methods 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 239000006260 foam Substances 0.000 claims description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 7
- 230000000087 stabilizing effect Effects 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- 101100112679 Caenorhabditis elegans cyd-1 gene Proteins 0.000 claims description 3
- 101100169267 Escherichia coli (strain K12) cydA gene Proteins 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 claims description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 2
- 101100169272 Escherichia coli (strain K12) cydB gene Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 108010004073 cysteinylcysteine Proteins 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229960001453 live attenuated japanese encephalitis Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 150000004043 trisaccharides Chemical class 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims 1
- 229960000974 live attenuated yellow fever Drugs 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 239000011325 microbead Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229940031351 tetravalent vaccine Drugs 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- 229940031346 monovalent vaccine Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000725619 Dengue virus Species 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000009477 glass transition Effects 0.000 description 3
- 229960001515 yellow fever vaccine Drugs 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000708009 Homo sapiens Sentrin-specific protease 8 Proteins 0.000 description 2
- 102100031407 Sentrin-specific protease 8 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000615954 Varroa destructor virus-1 Species 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 238000007444 cell Immobilization Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 238000004781 supercooling Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229940031418 trivalent vaccine Drugs 0.000 description 2
- 241000282465 Canis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 230000006910 ice nucleation Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
バッファー、
ソルビトール 2.5%〜6.5%
シュークロース 2.5%〜13%、
トレハロース 0〜7.5%および/または他の二糖もしくは三糖 0〜7.5%、
尿素 0.2%〜0.5%、
アルギニン(Arg)、シスチン(Cys−Cys)、ヒスチジン(His)、イソロイシン(Ile)、ロイシン(Leu)、リジン(Lys)、メチオニン(Met)、フェニルアラニン(Phe)、スレオニン(Thr)、トリプトファン(Trp)、チロシン(Tyr)、バリン(Val)、アラニン(Ala)、アスパラギン(Asn)、アスパラギン酸(Asp)、グルタミン酸(Glu)、グリシン(Gly)、プロリン(Pro)およびセリン(Ser)を含むアミノ酸混合物 0.8%〜2.5%
を含む安定化剤に関する。
ソルビトール 3.8%(w/v)、
シュークロース 7.5%(w/v)、
トレハロース 5.5%(w/v)、
尿素 0.25%(w/v)、および
アミノ酸混合物 1.5%(w/v)
を含む。
によって示される。形成された液滴の直径dは、
・凍結乾燥器の棚を−50℃に前冷却する。
・トレー識別のためにトレーにラベルを貼る。
・約1時間凍結乾燥器の棚上で取扱道具およびトレーを−50℃に冷却する。
特定の安定化賦形剤濃度が得られるようにキメラYF−DEN、血清型1、2、3または4(CYD−1、−2、−3または−4)を安定化剤と混合することによって一価組成物を調製した。多価組成物は、複数の一価組成物を混合することによって得られる。
選択された目的の濃度(log/ml)で最終組成物を得るように、キメラ黄熱−デング(VYD)ウイルスのバルクワクチン組成物の1つ、2つ、3つまたは4つを本発明の安定化剤と混合した後、これらの一価、二価、三価および四価のバルク混合物を冷凍または乾燥させることによってワクチン組成物を調製した。濃度は、各一価ワクチン組成物間で等しいかまたは選択された目的によって異なることができる。
実施例1の記載に従って、水性の一価、二価、三価または四価ワクチン組成物を得た。この撹拌した5℃の混合物をバイアル1つにつき0.3mlずつ可能な再現性のある方法で工業用凍結乾燥器の充填に必要な時間で分配した。次いで、棚を5℃に前冷却した凍結乾燥器中のラベルで識別されたトレー上に該バイアルを置いた。最終目的力価の該水性ワクチン組成物を含むバイアルを、以下に記載する凍結乾燥サイクルに従って凍結乾燥させた。このバイアルを−50℃に冷凍した。目的の温度が達成させると、各バイアルに含まれる冷凍ワクチン組成物を、第1昇華段階の間、50マイクロバールの圧力下にて棚温度−28℃で16.5時間昇華させた。次いで、凍結乾燥器中にて真空下または部分窒素圧下にてシェルフプレッシャーによって凍結乾燥バイアルに栓をした。該バイアルを取り出し、圧着し、標識し、次いで、5℃で貯蔵した。
安定化水性キメラ黄熱−デングバルク四価ワクチン組成物を6log/mlの目的濃度の本発明の安定化剤で安定化させた後、0.3mlずつ分配したバイアルを凍結乾燥させた。安定化四価ワクチン組成物の賦形剤の配合割合を下記表1に示す:
シュークロース7.5%/トレハロース5.5%の混合物をシュークロース13%に変更し、他の成分は変更しなかった。
トリスバッファーをHEPESバッファー0.36%に変更し、他の成分の配合割合は変更しなかった。
この研究は、実施例1の記載に従って生成し、凍結乾燥物質の形態(実施例2)または凍結乾燥マイクロビーズの形態で乾燥させた四価バルクワクチン組成物の安定性を比較した。図1に示された方法を用いて、凍結乾燥マイクロビーズを生成した。
−35℃の棚温度および50マイクロバールの圧力下で10時間の第1乾燥。
20℃の棚温度および50マイクロバールの圧力下での3時間の第2乾燥。
安定化水性キメラ黄熱−ウエストナイルバルクワクチン組成物を本発明の安定化剤で安定化した(実施例1および2に準じた)後、0.3mlずつ分配したバイアルを凍結乾燥させた(実施例3に準じた)。安定化凍結乾燥ワクチン組成物の賦形剤の配合割合は、実施例3の表1に示されている。並行して、安定化水性キメラ黄熱−ウエストナイルバルクワクチン組成物を、ヒト血清アルブミン(HSA)を含有する参照安定化剤で安定化した後、0.3mlずつ分配した凍結乾燥させた。
Claims (30)
- 1種類以上の弱毒生フラビウイルスを含むワクチン組成物用の安定化剤であって、動物起源のタンパク質を含まず、二価の陽イオンを有する塩を添加していない水性溶液中に
バッファー
ソルビトール 2.5%〜6.5%、
シュークロース 2.5%〜13%
トレハロース 0〜7.5%および/または他の二糖もしくは三糖 0〜7.5%
尿素 0.2〜0.5%、
アルギニン(Arg)、シスチン(Cys−Cys)、ヒスチジン(His)、イソロイシン(Ile)、ロイシン(Leu)、リジン(Lys)、メチオニン(Met)、フェニルアラニン(Phe)、スレオニン(Thr)、トリプトファン(Trp)、チロシン(Tyr)、バリン(Val)、アラニン(Ala)、アスパラギン(Asn)、アスパラギン酸(Asp)、グルタミン酸(Glu)、グリシン(Gly)、プロリン(Pro)およびセリン(Ser)を含むアミノ酸混合物 0.8%〜2.5%
を含む安定化剤。 - TRIS(トリス(ヒドロキシメチル)アミノメタン)、HEPES(2−(4−(2−ヒドロキシエチル)−1−ピペラジニル)エタンスルホン酸)およびリン酸カリウムおよび/またはリン酸ナトリウムからなる群から選択される1種類以上のバッファーを含有する、請求項1記載の安定化剤。
- TRISが5〜10mMの濃度で存在する、請求項2記載の安定化剤。
- HEPESが7.5〜20mMの濃度の濃度で存在する、請求項2記載の安定化剤。
- ソルビトール 3.8%(w/v)、
シュークロース 7.5%(w/v)、
トレハロース 5.5%(w/v)、
尿素 0.25%(w/v)、および
アミノ酸混合物 1.5%(w/v)
を含む、請求項1〜4いずれか1項記載の安定化剤。 - 1種類以上の弱毒生フラビウイルスおよび請求項1〜5いずれか1項記載の安定化剤を含む、安定化バルク水性ワクチン組成物。
- 1種類以上の弱毒生デング(DEN)ウイルス血清型を含む、請求項6記載の組成物。
- 弱毒生黄熱(YF)ウイルスを含む、請求項6または7記載の組成物。
- 弱毒生ウエストナイル(WN)ウイルス病ウイルスを含む、請求項6または8記載のワクチン組成物。
- 弱毒生日本脳炎(JE)ウイルスを含む、請求項6〜9いずれか1項記載のワクチン組成物。
- 1種類以上のキメラ弱毒生フラビウイルスを含む、請求項6〜10いずれか1項記載のワクチン組成物。
- キメラYF−DEN(黄熱−デング)ウイルスの1種類以上の血清型を含む、請求項11記載のワクチン組成物。
- キメラYF−WN(黄熱−ウエストナイルウイルス)ウイルスを含む、請求項11または12記載のワクチン組成物。
- キメラYF−JE(黄熱−日本脳炎)ウイルスを含む、請求項11〜13いずれか1項記載のワクチン組成物。
- CYD−1、CYD−2、CYD−3およびCYD−4を含む四価の組成物である、請求項6記載のワクチン組成物。
- 1種類以上の弱毒生フラビウイルスを安定化させる方法であって、請求項1〜5記載の安定化成分の最終濃度を得るように安定化剤を添加することによって1種類以上の弱毒生フラビウイルスを含む精製濃縮ウイルス収集物を希釈して請求項6〜15いずれか1項記載の組成物を得ることを含む、方法。
- 泡沫乾燥、スプレー乾燥または凍結泡沫乾燥からなる群から選択される方法によって水性組成物を乾燥させることを含む、請求項16記載の安定化方法。
- 凍結乾燥法によって水性組成物を乾燥させることを含む、請求項16記載の安定化方法。
- スプレー凍結乾燥法によって水性組成物を乾燥させることを含む、請求項16記載の安定化方法。
- 第1段階で水性溶液を均一粒子またはビーズの形態で凍結させ、第2段階でこの凍結均一粒子またはビーズを乾燥させて均一粒子またはビーズの形態の安定化乾燥生成物を得ることを特徴とする、請求項18または19記載の安定化方法。
- 安定化乾燥生成物の均一粒子またはビーズが100μm〜1500μmの直径を有する、請求項20記載の安定化方法。
- 安定化乾燥生成物の均一粒子またはビーズが500μm〜1000μmの直径を有する、請求項21記載の安定化方法。
- 請求項6〜15いずれか1項記載の安定化バルク組成物を乾燥させることによって得られる乾燥ワクチン組成物。
- 均一粒子またはビーズの形態で存在する、請求項23記載の乾燥ワクチン組成物。
- 各粒子または各ビーズが種々の弱毒生および/またはキメラ弱毒生フラビウイルスを含有する、請求項24記載の乾燥ワクチン組成物。
- 各粒子または各ビーズが弱毒生および/またはキメラ弱毒生フラビウイルスを含有する、請求項24記載の乾燥ワクチン組成物。
- 請求項6〜15いずれか1項記載の安定化バルク組成物から調製される乾燥ワクチン組成物。
- 請求項23〜27いずれか1項記載の組成物を水性溶液で再構成する工程を含む、ワクチンの調製方法。
- 請求項23〜27いずれか1項記載の乾燥ワクチン組成物が入っている第1容器およびワクチンを再構成するための水性溶液が入っている第2容器を含むフラビウイルスワクチンキット。
- 第1容器に請求項26記載の種々のワクチン組成物の混合物が入っている、請求項29記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08305390A EP2143440A1 (fr) | 2008-07-09 | 2008-07-09 | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
EP08305390.0 | 2008-07-09 | ||
PCT/EP2009/004980 WO2010003670A1 (en) | 2008-07-09 | 2009-07-09 | Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011527300A JP2011527300A (ja) | 2011-10-27 |
JP5586598B2 true JP5586598B2 (ja) | 2014-09-10 |
Family
ID=39942863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011517028A Active JP5586598B2 (ja) | 2008-07-09 | 2009-07-09 | 安定化剤、および1種類以上の弱毒生フラビウイルスを含むワクチン組成物 |
Country Status (17)
Country | Link |
---|---|
US (2) | US8142795B2 (ja) |
EP (3) | EP2143440A1 (ja) |
JP (1) | JP5586598B2 (ja) |
KR (1) | KR101679723B1 (ja) |
CN (1) | CN102089002B (ja) |
AR (1) | AR072796A1 (ja) |
AU (1) | AU2009267401B2 (ja) |
BR (1) | BRPI0915813B1 (ja) |
CA (1) | CA2729758C (ja) |
DK (1) | DK2310048T3 (ja) |
ES (1) | ES2429130T3 (ja) |
IL (1) | IL210289A0 (ja) |
MX (1) | MX2011000312A (ja) |
MY (1) | MY150613A (ja) |
TW (1) | TWI460190B (ja) |
WO (1) | WO2010003670A1 (ja) |
ZA (1) | ZA201100107B (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
ES2568942T3 (es) * | 2010-04-27 | 2016-05-05 | Universidad Manuela Beltrán | Vacuna biológica autóloga contra el cáncer |
FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
WO2012028315A1 (en) | 2010-09-02 | 2012-03-08 | Sanofi Pasteur Sa | A stabilizer for the preparation of a dry polio injectable vaccine composition |
DK2741740T3 (en) | 2011-08-12 | 2017-06-06 | Merial Inc | VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES |
CA2859916C (en) | 2012-01-09 | 2021-02-09 | Sanofi Pasteur Biologics, Llc | Purification of herpes virus |
ES2682024T3 (es) * | 2012-05-14 | 2018-09-18 | Teijin Limited | Composición de proteína resistente a la esterilización por radiación |
EP2852662B1 (en) * | 2012-05-21 | 2020-09-16 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
KR20200067938A (ko) | 2012-07-24 | 2020-06-12 | 사노피 파스퇴르 | 백신 조성물 |
MX2015000446A (es) | 2012-07-24 | 2015-03-12 | Sanofi Pasteur | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue. |
US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
WO2014083194A1 (en) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
CA2927434C (en) * | 2013-10-16 | 2022-07-19 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
CA2927431C (en) | 2013-10-16 | 2023-10-03 | Merck Sharp & Dohme Corp. | Method of microwave vacuum drying spherical-shaped pellets of biological materials |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
CA2948845C (en) | 2014-05-14 | 2022-05-31 | Merial, Inc. | Methods for freeze-drying and rehydrating biologics |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
EP3316905A1 (en) | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
CN106667944A (zh) * | 2015-11-11 | 2017-05-17 | 北京泰德制药股份有限公司 | 含有前列腺素类药物的缓释制剂 |
TWI766876B (zh) | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
US11166915B2 (en) * | 2016-09-16 | 2021-11-09 | Leukocare Ag | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
US11052147B2 (en) * | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3681998A1 (en) | 2017-09-11 | 2020-07-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Tumor organoid model |
WO2019069130A1 (en) | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
UA127829C2 (uk) * | 2017-10-16 | 2024-01-17 | Сірем Інстітьют Оф Індіа Прайвет Лімітед | Стабільна ліофілізована імуногенна композиція, яка містить живий атенуйований рекомбінантний флавівірус, спосіб і набір для її отримання та застосування |
WO2019112921A1 (en) * | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
CN108938574B (zh) * | 2018-08-14 | 2020-10-16 | 江苏省农业科学院 | 猪伪狂犬病活疫苗冻干耐热保护剂、其制备方法及用途 |
US20220193222A1 (en) * | 2018-11-30 | 2022-06-23 | Vaccine Stabilization Institute | Viral formulations containing amino acids |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3162019A (en) | 1962-11-16 | 1964-12-22 | Bethlehem Steel Corp | Method and apparatus for freezing liquids to be used in a freeze-drying process |
GB1195363A (en) | 1966-06-17 | 1970-06-17 | Struthers Scientific Int Corp | Freeze Drying |
US3313032A (en) | 1966-07-28 | 1967-04-11 | George J Malecki | Freeze-drying process and apparatus |
US3655838A (en) | 1969-03-20 | 1972-04-11 | Organon | Method of pelletizing analytical or immunological reagents |
DE2659546A1 (de) | 1976-12-30 | 1978-07-13 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von gefrorenen granulaten |
US4211015A (en) | 1978-01-18 | 1980-07-08 | Baxter Travenol Laboratories, Inc. | Method and apparatus for making novel particulate compositions |
FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
GB8802142D0 (en) | 1988-02-01 | 1988-03-02 | Air Prod & Chem | Method of freezing liquid & pasty products & freezer for carrying out said method |
ATE310824T1 (de) | 1991-09-19 | 2005-12-15 | Chimäre und/oder wachstumsgehemmte flaviviren | |
US5307640A (en) | 1993-01-25 | 1994-05-03 | E. I. Du Pont De Nemours And Company | Apparatus and method for producing frozen particles of a liquid |
US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
FR2742756B1 (fr) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
IL120202A (en) * | 1996-03-07 | 2001-03-19 | Akzo Nobel Nv | Container with freeze-dried vaccine components |
ES2345614T3 (es) | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
JP2002540166A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱3型ウイルスワクチン |
JP2002540171A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱4型ウイルスワクチン |
CA2365728A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
AU4040200A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
ES2374131T3 (es) | 2000-02-16 | 2012-02-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Flavivirus quiméricos avirulentos e inmunógenos. |
DE60040652D1 (de) | 2000-05-30 | 2008-12-11 | Univ Mahidol | Attenuierte Stammen von Denguevirus und ihre Verwendungen in Impfstoffzusammensetzungen |
US6862890B2 (en) | 2001-01-30 | 2005-03-08 | Board Of Regents, University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
AT410634B (de) * | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
GB2372991B (en) | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
DE10124902A1 (de) | 2001-05-22 | 2002-11-28 | Bayer Ag | Partikuläre Feststoffe oberflächenaktiver Verbindungen |
DK2290109T3 (da) | 2001-05-22 | 2014-11-10 | Us Gov Health & Human Serv | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira |
EP1401859B1 (en) | 2001-06-01 | 2013-08-07 | Sanofi Pasteur Biologics Co. | Chimeric flavivirus vectors |
BR122018075729B8 (pt) | 2002-01-15 | 2021-07-27 | Acambis Inc | flavivírus na preparação de uma composição de vacina |
US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
NZ535690A (en) | 2002-02-26 | 2009-04-30 | Maxygen Inc | Novel flavivirus antigens |
CA2482448C (en) * | 2002-04-11 | 2014-07-08 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
US20030215455A1 (en) * | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
ES2337893T3 (es) | 2002-11-15 | 2010-04-30 | Sanofi Pasteur Biologics Co. | Vacuna del virus del nilo occidental. |
US20040213808A1 (en) * | 2002-12-11 | 2004-10-28 | Michael Lieberman | Recombinant vaccine against flavivirus infection |
JP4829229B2 (ja) | 2004-07-23 | 2011-12-07 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 無菌凍結、乾燥、保存、分析及び充填方法(sfd−saf法)(非経口生物薬剤用のペレット凍結乾燥法) |
ATE475706T1 (de) | 2005-06-17 | 2010-08-15 | Sanofi Pasteur | Abgeschwächter dengue-serotyp-2-stamm |
AU2006257610B2 (en) | 2005-06-17 | 2012-11-15 | Centers For Disease Control And Prevention | Dengue serotype 1 attenuated strain |
EP1909839A1 (en) * | 2005-08-04 | 2008-04-16 | Wyeth a Corporation of the State of Delaware | Stabilizers for veterinary vaccines |
EP1951865A4 (en) * | 2005-11-21 | 2010-06-23 | Sanofi Pasteur Ltd | STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES |
FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
CA2663892A1 (en) | 2006-09-25 | 2008-04-03 | Medimmune, Llc | Stabilized antibody formulations and uses thereof |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
AR063606A1 (es) | 2006-11-07 | 2009-02-04 | Acambis Inc | Estabilizacion de vacunas mediante liofilizacion |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
CN104998257A (zh) * | 2007-04-06 | 2015-10-28 | 武田疫苗公司 | 用于活的减毒病毒的方法和组合物 |
-
2008
- 2008-07-09 EP EP08305390A patent/EP2143440A1/fr not_active Withdrawn
-
2009
- 2009-07-06 AR ARP090102524A patent/AR072796A1/es not_active Application Discontinuation
- 2009-07-08 TW TW098123127A patent/TWI460190B/zh active
- 2009-07-09 BR BRPI0915813-8A patent/BRPI0915813B1/pt active IP Right Grant
- 2009-07-09 WO PCT/EP2009/004980 patent/WO2010003670A1/en active Application Filing
- 2009-07-09 EP EP09793888.0A patent/EP2310048B1/en active Active
- 2009-07-09 CN CN200980127083.8A patent/CN102089002B/zh active Active
- 2009-07-09 DK DK09793888.0T patent/DK2310048T3/da active
- 2009-07-09 MX MX2011000312A patent/MX2011000312A/es active IP Right Grant
- 2009-07-09 MY MYPI20105959 patent/MY150613A/en unknown
- 2009-07-09 CA CA2729758A patent/CA2729758C/en active Active
- 2009-07-09 JP JP2011517028A patent/JP5586598B2/ja active Active
- 2009-07-09 ES ES09793888T patent/ES2429130T3/es active Active
- 2009-07-09 US US12/500,156 patent/US8142795B2/en active Active
- 2009-07-09 AU AU2009267401A patent/AU2009267401B2/en active Active
- 2009-07-09 KR KR1020117000182A patent/KR101679723B1/ko active IP Right Grant
- 2009-07-09 EP EP13183819.5A patent/EP2687229A1/en not_active Withdrawn
-
2010
- 2010-12-27 IL IL210289A patent/IL210289A0/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00107A patent/ZA201100107B/en unknown
-
2012
- 2012-03-26 US US13/429,542 patent/US20130028934A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2310048B1 (en) | 2013-09-11 |
IL210289A0 (en) | 2011-03-31 |
CN102089002B (zh) | 2014-12-10 |
EP2687229A1 (en) | 2014-01-22 |
EP2143440A1 (fr) | 2010-01-13 |
US20130028934A1 (en) | 2013-01-31 |
JP2011527300A (ja) | 2011-10-27 |
CA2729758A1 (en) | 2010-01-14 |
US20100015180A1 (en) | 2010-01-21 |
TWI460190B (zh) | 2014-11-11 |
BRPI0915813B1 (pt) | 2022-02-08 |
MY150613A (en) | 2014-01-30 |
DK2310048T3 (da) | 2013-10-07 |
WO2010003670A1 (en) | 2010-01-14 |
AU2009267401B2 (en) | 2014-12-11 |
AU2009267401A1 (en) | 2010-01-14 |
US8142795B2 (en) | 2012-03-27 |
ES2429130T3 (es) | 2013-11-13 |
EP2310048A1 (en) | 2011-04-20 |
ZA201100107B (en) | 2012-03-28 |
AR072796A1 (es) | 2010-09-22 |
TW201014868A (en) | 2010-04-16 |
CN102089002A (zh) | 2011-06-08 |
CA2729758C (en) | 2017-03-07 |
MX2011000312A (es) | 2011-03-01 |
KR101679723B1 (ko) | 2016-11-25 |
KR20110053325A (ko) | 2011-05-20 |
BRPI0915813A2 (pt) | 2019-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5586598B2 (ja) | 安定化剤、および1種類以上の弱毒生フラビウイルスを含むワクチン組成物 | |
JP5687836B2 (ja) | 凍結乾燥によるワクチンの安定化 | |
AU2010304898B2 (en) | Stabilising excipient for inactivated whole-virus vaccines | |
TW575433B (en) | Process for the manufacture of amorphous products by means of convection drying | |
TWI812650B (zh) | 包含特別是減毒活重組黃病毒的穩定疫苗組成物以及製備其的製程 | |
EP2552465B1 (en) | Stabilisation of viral particles | |
JP6253161B2 (ja) | 乾燥された生物学的材料を安定化するための方法及び組成物 | |
CN105579059A (zh) | 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针 | |
CA2873775C (en) | Herpesvirus compositions and related methods | |
Zuo et al. | Live vaccine preserved at room temperature: Preparation and characterization of a freeze-dried classical swine fever virus vaccine | |
Kanojia et al. | The effect of formulation on spray dried Sabin inactivated polio vaccine | |
CN106687132B (zh) | 改进的热稳定喷雾干燥轮状病毒疫苗制剂及其制备方法 | |
EA046342B1 (ru) | Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус и процесс их приготовления | |
ES2788324T3 (es) | Métodos y composiciones para estabilizar materiales biológicos secos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120525 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140715 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140722 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5586598 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |